Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2CH5N3.H2O4S |
| Molecular Weight | 216.219 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(N)=N.NC(N)=N.OS(O)(=O)=O
InChI
InChIKey=UYAKTBUPMOOXNW-UHFFFAOYSA-N
InChI=1S/2CH5N3.H2O4S/c2*2-1(3)4;1-5(2,3)4/h2*(H5,2,3,4);(H2,1,2,3,4)
Guanidine is a small basic compound. Guanidine stimulates the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to the enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases. The hydrochloride salt of guanidine was approved by FDA for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert.
Originator
Sources: https://d-nb.info/1059797615/34
Curator's Comment: Original article: A. Strecker, Liebigs Ann. Chem. 1861, 118, 151-177.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2362996 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | GUANIDINE HYDROCHLORIDE Approved UseGuanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis. The Eaton-Lambert syndrome is ordinarily differentiated from myasthenia gravis by the usual association of the syndrome with small cell carcinoma of the lung, but myography may be necessary to make the diagnosis. Launch Date1939 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The relationship of the factor V Leiden mutation or the deletion-deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty. | 2001 |
|
| Isolation and characterization of a xylose-glucose isomerase from a new strain Streptomyces thermovulgaris 127, var. 7-86. | 2001 |
|
| Topological diversity of artificial beta-barrels in water. | 2001 |
|
| Dihydrofolate reductase from Thermotoga maritima. | 2001 |
|
| Evolution and physiological roles of phosphagen systems. | 2001 |
|
| Structure-activity relationship (SAR) studies on oxazolidinone antibacterial agents. 1. Conversion of 5-substituent on oxazolidinone. | 2001 Apr |
|
| Demineralized bone matrix as a biological scaffold for bone repair. | 2001 Apr |
|
| Kinetics of unfolding and folding from amide hydrogen exchange in native ubiquitin. | 2001 Apr |
|
| Total chemical synthesis of human matrix Gla protein. | 2001 Apr |
|
| Strain-specified relative conformational stability of the scrapie prion protein. | 2001 Apr |
|
| The structure of human mitochondrial branched-chain aminotransferase. | 2001 Apr |
|
| Guanidine-induced equilibrium unfolding of a homo-hexameric enzyme 4-oxalocrotonate tautomerase (4-OT). | 2001 Apr 10 |
|
| Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent. | 2001 Apr 12 |
|
| Structure--function relationships in bovine thymus 20S proteasome: a fluorimetric study. | 2001 Apr 12 |
|
| Second-site revertants of a low-sodium-affinity mutant of the Na+/H+ exchanger reveal the participation of TM4 into a highly constrained sodium-binding site. | 2001 Apr 24 |
|
| Equilibrium unfolding of dimeric desulfoferrodoxin involves a monomeric intermediate: iron cofactors dissociate after polypeptide unfolding. | 2001 Apr 24 |
|
| Characterization of the denatured states distribution of neocarzinostatin by small-angle neutron scattering and differential scanning calorimetry. | 2001 Apr 3 |
|
| Isolation and spectroscopic characterization of the structural subunits of keyhole limpet hemocyanin. | 2001 Apr 7 |
|
| Intensely positively charged perineuronal nets in the adult rat brain as detected by staining with anionic iron colloid. | 2001 Feb |
|
| Probing copper ligands in denatured Pseudomonas aeruginosa azurin: unfolding His117Gly and His46Gly mutants. | 2001 Feb |
|
| Species-specific PCR for the identification of ovine, porcine and chicken species in meta and bone meal (MBM). | 2001 Feb |
|
| Human recombinant interferon-inducible protein-10: intact disulfide bridges are not required for inhibition of hematopoietic progenitors and chemotaxis of T lymphocytes and monocytes. | 2001 Feb |
|
| Stabilization of hen egg white lysozyme by a cavity-filling mutation. | 2001 Feb |
|
| Metric engineering of soft molecular host frameworks. | 2001 Feb |
|
| [Discovery of cis-preference of aromatic N-methylamides and its application to molecular constructions]. | 2001 Feb |
|
| Spontaneous and flow-induced Ca2+ transients in retracted regions in endothelial cells. | 2001 Feb 16 |
|
| Molecular specificities of antibodies against ovine and murine recombinant prion proteins. | 2001 Feb 16 |
|
| Efficient gene transfection by bisguanylated diacetylene lipid formulations. | 2001 Feb 23 |
|
| Engineering conformational flexibility in the lactose permease of Escherichia coli: use of glycine-scanning mutagenesis to rescue mutant Glu325-->Asp. | 2001 Jan 23 |
|
| [Y97V substitution in the horse cytochrome c causes accumulation of the equilibrium intermediate]. | 2001 Jan-Feb |
|
| Protein compactness measured by fluorescence resonance energy transfer. Human carbonic anhydrase ii is considerably expanded by the interaction of GroEL. | 2001 Jun 15 |
|
| Structural basis of the Na+/H+ exchanger regulatory factor PDZ1 interaction with the carboxyl-terminal region of the cystic fibrosis transmembrane conductance regulator. | 2001 Jun 8 |
|
| alpha Arg-237 in Methylophilus methylotrophus (sp. W3A1) electron-transferring flavoprotein affords approximately 200-millivolt stabilization of the FAD anionic semiquinone and a kinetic block on full reduction to the dihydroquinone. | 2001 Jun 8 |
|
| Elucidation of a [4Fe-4S] cluster degradation pathway: rapid kinetic studies of the degradation of Chromatium vinosum HiPIP. | 2001 Mar |
|
| Virus inactivation of plasma-derived proteins by pasteurization in the presence of guanidine hydrochloride. | 2001 Mar |
|
| Proteoglycans and hyaluronan in human fetal membranes. | 2001 Mar |
|
| Characterization of carbonic anhydrase from Neisseria gonorrhoeae. | 2001 Mar |
|
| Major differences in stability and dimerization properties of two chimeric mutants of human stefins. | 2001 Mar 1 |
|
| The synthesis of beta-peptides containing guanidino groups. | 2001 Mar 12 |
|
| Mutagenesis of two acidic active site residues in human muscle creatine kinase: implications for the catalytic mechanism. | 2001 Mar 13 |
|
| Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic. | 2001 Mar 15 |
|
| Probing local conformational changes during equilibrium unfolding of firefly luciferase: fluorescence and circular dichroism studies of single tryptophan mutants. | 2001 Mar 23 |
|
| Dramatic stabilization of an SH3 domain by a single substitution: roles of the folded and unfolded states. | 2001 Mar 30 |
|
| The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain. | 2001 Mar 30 |
|
| Osmolytes protect mitochondrial F(0)F(1)-ATPase complex against pressure inactivation. | 2001 Mar 9 |
|
| Proton and metal ion-dependent assembly of a model diiron protein. | 2001 May |
|
| Cyclic green fluorescent protein produced in vivo using an artificially split PI-PfuI intein from Pyrococcus furiosus. | 2001 May 11 |
|
| Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology. | 2001 May 15 |
|
| Replacement of thrombin residue G184 with Lys or Arg fails to mimic Na+ binding. | 2001 May 15 |
|
| Folding intermediates of a model three-helix bundle protein. Pressure and cold denaturation studies. | 2001 May 4 |
Sample Use Guides
Initial dosage is usually between 10 and 15 mg/kg (5 to 7 mg/pound) of body weight per day in 3 or 4 divided doses. This dosage may be gradually increased to a total daily dosage of 35 mg/kg (16 mg/pound) of body weight per day or up to the development of side effects.
Route of Administration:
Oral
Mice spinal cord neurons were treated with guanidine at concentrations between 100 nM and 100 mM. At 100 mM induced a membrane depolarization of 10 to 25 mV and rapidly and reversibly reduced GABA responses: 23.9% decrease of GABA responses was obtained with 10 mM guanidine and complete inhibition was observed with 100 mM). It also significantly reduced Glycine response at 10 mM.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID00883456
Created by
admin on Sat Dec 16 08:26:47 GMT 2023 , Edited by admin on Sat Dec 16 08:26:47 GMT 2023
|
PRIMARY | |||
|
594-14-9
Created by
admin on Sat Dec 16 08:26:47 GMT 2023 , Edited by admin on Sat Dec 16 08:26:47 GMT 2023
|
PRIMARY | |||
|
QB1C462BAB
Created by
admin on Sat Dec 16 08:26:47 GMT 2023 , Edited by admin on Sat Dec 16 08:26:47 GMT 2023
|
PRIMARY | |||
|
209-826-8
Created by
admin on Sat Dec 16 08:26:47 GMT 2023 , Edited by admin on Sat Dec 16 08:26:47 GMT 2023
|
PRIMARY | |||
|
7296
Created by
admin on Sat Dec 16 08:26:47 GMT 2023 , Edited by admin on Sat Dec 16 08:26:47 GMT 2023
|
PRIMARY | |||
|
2735051
Created by
admin on Sat Dec 16 08:26:47 GMT 2023 , Edited by admin on Sat Dec 16 08:26:47 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
